KRYS news

Krystal Biotech reported that KB113 demonstrated over 80% regression of basal cell carcinomas in patients with Gorlin syndrome, showing a systemic immune response. This positive trial data supports the continued development of the therapy.

Krystal Bio reported $119.2M in VYJUVEK revenue for Q2 2026, showcasing growing commercial traction. Maintaining a $1.1B cash balance, the company is on track for launches in Spain and Italy and advancing multiple registrations.

Krystal Biotech reversed previous full-year guidance to reflect substantial contributions to revenue from OCLs, the Antares ZRN-401 combination product will be considered in guidance, and the guidance downgrade materializes following the agreement to acquire VectivBio. The guidance is based on preli…

Quince Therapeutics adopted a 1-for-20 reverse stock split effective June 2026 following board and shareholder approval. This corporate restructuring consolidates outstanding shares to potentially bolster the market price per share.